BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

501 related articles for article (PubMed ID: 30089584)

  • 1. An updated and validated PET/CT volumetric prognostic index for non-small cell lung cancer.
    Finkle JH; Penney BC; Pu Y
    Lung Cancer; 2018 Sep; 123():136-141. PubMed ID: 30089584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new PET/CT volumetric prognostic index for non-small cell lung cancer.
    Zhang H; Wroblewski K; Jiang Y; Penney BC; Appelbaum D; Simon CA; Salgia R; Pu Y
    Lung Cancer; 2015 Jul; 89(1):43-9. PubMed ID: 25936471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Developing and validating a novel metabolic tumor volume risk stratification system for supplementing non-small cell lung cancer staging.
    Pu Y; Zhang JX; Liu H; Appelbaum D; Meng J; Penney BC
    Eur J Nucl Med Mol Imaging; 2018 Nov; 45(12):2079-2092. PubMed ID: 29882161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of quantitative PET/CT in patients with a nonsmall cell lung cancer and another primary cancer.
    Zhu X; Liao C; Penney BC; Li F; Ferguson MK; Simon CA; Wu T; Liu H; Pu Y
    Nucl Med Commun; 2017 Feb; 38(2):185-192. PubMed ID: 27922540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Developing a clinical and PET/CT volumetric prognostic index for risk assessment and management of NSCLC patients after initial therapy.
    Liu L; Zhang J; Ferguson MK; Appelbaum D; Zhang JX; Pu Y
    Front Biosci (Landmark Ed); 2022 Jan; 27(1):16. PubMed ID: 35090321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk-stratifying capacity of PET/CT metabolic tumor volume in stage IIIA non-small cell lung cancer.
    Finkle JH; Jo SY; Ferguson MK; Liu HY; Zhang C; Zhu X; Yuan C; Pu Y
    Eur J Nucl Med Mol Imaging; 2017 Aug; 44(8):1275-1284. PubMed ID: 28265739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic active tumour volume quantified on [
    Rocha ALG; da Conceição MAM; da Cunha Sequeira Mano FXP; Martins HC; Costa GMLM; Dos Santos Oliveiros Paiva BCB; Lapa PAA
    J Cancer Res Clin Oncol; 2021 Dec; 147(12):3601-3611. PubMed ID: 34570257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
    Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
    Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Independent prognostic value of whole-body metabolic tumor burden from FDG-PET in non-small cell lung cancer.
    Zhang H; Wroblewski K; Appelbaum D; Pu Y
    Int J Comput Assist Radiol Surg; 2013 Mar; 8(2):181-91. PubMed ID: 22644386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between Overall Survival of Patients with Non-Small Cell Lung Cancer and Whole-Body Metabolic Tumor Burden Seen on Postsurgical Fluorodeoxyglucose PET Images.
    Zhang C; Liao C; Penney BC; Appelbaum DE; Simon CA; Pu Y
    Radiology; 2015 Jun; 275(3):862-9. PubMed ID: 25584710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic tumor burden quantified on [
    Lapa P; Oliveiros B; Marques M; Isidoro J; Alves FC; Costa JMN; Costa G; de Lima JP
    Eur J Nucl Med Mol Imaging; 2017 Dec; 44(13):2169-2178. PubMed ID: 28785842
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of tumor burden measurement using the number of tumors in non-surgical patients with non-small cell lung cancer.
    Zhang H; Wroblewski K; Pu Y
    Acta Radiol; 2012 Jun; 53(5):561-8. PubMed ID: 22661603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of metabolic tumor volume of pretreatment
    Kumasaka S; Nakajima T; Arisaka Y; Tokue A; Achmad A; Fukushima Y; Shimizu K; Kaira K; Higuchi T; Tsushima Y
    BMC Med Imaging; 2018 Nov; 18(1):46. PubMed ID: 30477476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Whole body metabolic tumor volume is a prognostic marker in patients with newly diagnosed stage 3B non-small cell lung cancer, confirmed with external validation.
    Dashevsky BZ; Zhang C; Yan L; Yuan C; Xiong L; Liu Y; Liu H; Kong FS; Pu Y
    Eur J Hybrid Imaging; 2017; 1(1):8. PubMed ID: 29782599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimal FDG PET/CT volumetric parameters for risk stratification in patients with locally advanced non-small cell lung cancer: results from the ACRIN 6668/RTOG 0235 trial.
    Salavati A; Duan F; Snyder BS; Wei B; Houshmand S; Khiewvan B; Opanowski A; Simone CB; Siegel BA; Machtay M; Alavi A
    Eur J Nucl Med Mol Imaging; 2017 Nov; 44(12):1969-1983. PubMed ID: 28689281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Volume-based parameters of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography improve outcome prediction in early-stage non-small cell lung cancer after surgical resection.
    Hyun SH; Choi JY; Kim K; Kim J; Shim YM; Um SW; Kim H; Lee KH; Kim BT
    Ann Surg; 2013 Feb; 257(2):364-70. PubMed ID: 22968069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic Significance of FDG Uptake of Bone Marrow on PET/CT in Patients With Non-Small-Cell Lung Cancer After Curative Surgical Resection.
    Lee JW; Na JO; Kang DY; Lee SY; Lee SM
    Clin Lung Cancer; 2017 Mar; 18(2):198-206. PubMed ID: 27495385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer.
    Chen HH; Chiu NT; Su WC; Guo HR; Lee BF
    Radiology; 2012 Aug; 264(2):559-66. PubMed ID: 22692034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of primary tumor metabolic volume during chemoradiotherapy in locally advanced non-small cell lung cancer.
    Roengvoraphoj O; Wijaya C; Eze C; Li M; Dantes M; Taugner J; Tufman A; Huber RM; Belka C; Manapov F
    Strahlenther Onkol; 2018 Feb; 194(2):107-115. PubMed ID: 29116336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of Various Metabolic Parameters Derived From Baseline 18F-FDG PET/CT as Prognostic Markers in Non-Small Cell Lung Cancer Patients Undergoing Platinum-Based Chemotherapy.
    Sharma A; Mohan A; Bhalla AS; Sharma MC; Vishnubhatla S; Das CJ; Pandey AK; Sekhar Bal C; Patel CD; Sharma P; Agarwal KK; Kumar R
    Clin Nucl Med; 2018 Jan; 43(1):e8-e17. PubMed ID: 29112011
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.